Literature DB >> 2297579

Expression of human glucocerebrosidase in murine long-term bone marrow cultures after retroviral vector-mediated transfer.

J A Nolta1, L S Sender, J A Barranger, D B Kohn.   

Abstract

A retroviral vector (N2-SV-GC) was constructed by inserting a normal human glucocerebrosidase (GC) cDNA under control of the SV40 early region promoter into the Moloney murine leukemia virus-derived N2 vector. N2-SV-GC produced human GC in murine 3T3 fibroblasts at levels in the range of the endogenous murine GC as determined by enzymatic assay and Western blot analysis. The N2-SV-GC retroviral vector was used for studies of gene transduction of murine hematopoietic progenitor cells (HPC). Infection of bone marrow cultured for 2 to 10 days in medium containing hematopoietic growth factors was significantly more efficient than infection of freshly isolated marrow cells (24% to 32% G418-resistant CFU-GM v 15%, respectively). The marrow infected by N2-SV-GC was maintained in long-term bone marrow culture (LTBMC) and had a stable level of G418-resistant HPC over 2 months of serial assays. The human GC gene of the vector was persistently expressed in the nonadherent cell fraction of the murine LTBMC as determined by Northern blotting, Western blotting, and immunohistochemical staining using a monoclonal antibody specific for human GC. N2-SV-GC also expressed the human GC gene in day 12 CFU-S. LTBMC represents a novel system for retroviral vector-mediated gene transduction of HPC and may accurately predict the activities of vectors in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297579

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 2.  Lysosomal storage diseases: mechanisms of enzyme replacement therapy.

Authors:  G Bou-Gharios; D Abraham; I Olsen
Journal:  Histochem J       Date:  1993-09

Review 3.  Gaucher disease as a paradigm of current issues regarding single gene mutations of humans.

Authors:  E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

4.  VP22 enhances the expression of glucocerebrosidase in human Gaucher II fibroblast cells mediated by lentiviral vectors.

Authors:  Gui-shan Jin; Gui-dong Zhu; Zhi-gang Zhao; Fu-sheng Liu
Journal:  Clin Exp Med       Date:  2011-08-28       Impact factor: 3.984

5.  Effective cell and gene therapy in a murine model of Gaucher disease.

Authors:  Ida Berglin Enquist; Eva Nilsson; Andreas Ooka; Jan-Eric Månsson; Karin Olsson; Mats Ehinger; Roscoe O Brady; Johan Richter; Stefan Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-05       Impact factor: 11.205

6.  Phenotypic and genotypic heterogeneity in gaucher disease: Implications for genetic counseling.

Authors:  E Sidransky; E I Ginns
Journal:  J Genet Couns       Date:  1994-03       Impact factor: 2.537

7.  Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.

Authors:  J A Nolta; X J Yu; I Bahner; D B Kohn
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

8.  Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector.

Authors:  T Ohashi; S Boggs; P Robbins; A Bahnson; K Patrene; F S Wei; J F Wei; J Li; L Lucht; Y Fei
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.